ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Neuroscience

Roche signs license agreement for UCB’s tau-targeting antibody

by Ryan Cross
July 31, 2020 | APPEARED IN VOLUME 98, ISSUE 30

 

Roche will pay $120 million to license UCB0107, an experimental antibody treatment for Alzheimer’s disease developed by the Belgian firm UCB. The antibody targets tau, a protein implicated in Alzheimer’s. After UCB runs a proof-of-concept study, Roche will decide whether to continue developing the antibody or return full rights to UCB. If successful, UCB could earn nearly $2 billion in milestone payments from Roche. Last year, Roche ended two late-stage studies of an antibody that targeted amyloid beta.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment